Cargando…

Sustained inhibition of progressive joint damage with rituximab plus methotrexate in early active rheumatoid arthritis: 2-year results from the randomised controlled trial IMAGE

BACKGROUND: In the IMAGE study, rituximab plus methotrexate (MTX) inhibited joint damage and improved clinical outcomes at 1 year in MTX-naïve patients with early active rheumatoid arthritis. OBJECTIVE: The aim of this study was to assess joint damage progression and clinical outcomes over 2 years....

Descripción completa

Detalles Bibliográficos
Autores principales:	Tak, Paul P, Rigby, William, Rubbert-Roth, Andrea, Peterfy, Charles, van Vollenhoven, Ronald F, Stohl, William, Healy, Emma, Hessey, Eva, Reynard, Mark, Shaw, Tim
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Group 2011
Materias:	Clinical and Epidemiological Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3277723/ https://www.ncbi.nlm.nih.gov/pubmed/22012969 http://dx.doi.org/10.1136/annrheumdis-2011-200170

Ejemplares similares

Tocilizumab combination therapy or monotherapy or methotrexate monotherapy in methotrexate-naive patients with early rheumatoid arthritis: 2-year clinical and radiographic results from the randomised, placebo-controlled FUNCTION trial
por: Burmester, Gerd R, et al.
Publicado: (2017)

Continued inhibition of structural damage over 2 years in patients with rheumatoid arthritis treated with rituximab in combination with methotrexate
por: Cohen, Stanley B, et al.
Publicado: (2010)

Tocilizumab in early progressive rheumatoid arthritis: FUNCTION, a randomised controlled trial
por: Burmester, Gerd R, et al.
Publicado: (2016)

Predictors of disease activity and structural progression after treatment with adalimumab plus methotrexate or continued methotrexate monotherapy in patients with early rheumatoid arthritis and suboptimal response to methotrexate
por: Smolen, Josef S, et al.
Publicado: (2018)

Testing treat-to-target outcomes with initial methotrexate monotherapy compared with initial tumour necrosis factor inhibitor (adalimumab) plus methotrexate in early rheumatoid arthritis
por: Kavanaugh, Arthur, et al.
Publicado: (2018)

Association of joint space narrowing with impairment of physical function and work ability in patients with early rheumatoid arthritis: protection beyond disease control by adalimumab plus methotrexate
por: Smolen, Josef S, et al.
Publicado: (2013)

Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial
por: Smolen, J, et al.
Publicado: (2008)

Certolizumab pegol plus methotrexate provides broad relief from the burden of rheumatoid arthritis: analysis of patient-reported outcomes from the RAPID 2 trial
por: Strand, Vibeke, et al.
Publicado: (2011)

Safety and efficacy of ocrelizumab in combination with methotrexate in MTX-naive subjects with rheumatoid arthritis: the phase III FILM trial
por: Stohl, William, et al.
Publicado: (2012)

Impact of intravenous abatacept on synovitis, osteitis and structural damage in patients with rheumatoid arthritis and an inadequate response to methotrexate: the ASSET randomised controlled trial
por: Conaghan, Philip G, et al.
Publicado: (2013)

MRI assessment of suppression of structural damage in patients with rheumatoid arthritis receiving rituximab: results from the randomised, placebo-controlled, double-blind RA-SCORE study
por: Peterfy, Charles, et al.
Publicado: (2016)

Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naïve with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab's Efficacy in MTX iNadequate rEsponders (SERENE))
por: Emery, P, et al.
Publicado: (2010)

Clinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factors
por: Westhovens, R, et al.
Publicado: (2009)

A randomised, double-blind trial to demonstrate bioequivalence of GP2013 and reference rituximab combined with methotrexate in patients with active rheumatoid arthritis
por: Smolen, Josef S, et al.
Publicado: (2017)

Infliximab plus methotrexate is superior to methotrexate alone in the treatment of psoriatic arthritis in methotrexate-naive patients: the RESPOND study
por: Baranauskaite, Asta, et al.
Publicado: (2011)

Efficacy and safety of various repeat treatment dosing regimens of rituximab in patients with active rheumatoid arthritis: results of a Phase III randomized study (MIRROR)
por: Rubbert-Roth, Andrea, et al.
Publicado: (2010)

Successful Treatment of Rituximab-Associated Palmoplantar Pustulosis With Apremilast in a Patient With Seropositive Rheumatoid Arthritis
por: Haller, Christoph, et al.
Publicado: (2021)

Quantifying the hepatotoxic risk of alcohol consumption in patients with rheumatoid arthritis taking methotrexate
por: Humphreys, Jenny H, et al.
Publicado: (2017)

Retreatment with rituximab based on a treatment-to-target approach provides better disease control than treatment as needed in patients with rheumatoid arthritis: a retrospective pooled analysis
por: Emery, Paul, et al.
Publicado: (2011)

Achieving comprehensive disease control in patients with early and established rheumatoid arthritis treated with adalimumab plus methotrexate versus methotrexate alone
por: Keystone, Edward C, et al.
Publicado: (2017)

Long-term safety, efficacy and inhibition of radiographic progression with abatacept treatment in patients with rheumatoid arthritis and an inadequate response to methotrexate: 3-year results from the AIM trial
por: Kremer, Joel M, et al.
Publicado: (2011)

Effect of tocilizumab on neutrophils in adult patients with rheumatoid arthritis: pooled analysis of data from phase 3 and 4 clinical trials
por: Moots, Robert J., et al.
Publicado: (2017)

Rituximab versus an alternative TNF inhibitor in patients with rheumatoid arthritis who failed to respond to a single previous TNF inhibitor: SWITCH-RA, a global, observational, comparative effectiveness study
por: Emery, P, et al.
Publicado: (2015)

Filgotinib in combination with methotrexate or as monotherapy versus methotrexate monotherapy in patients with active rheumatoid arthritis and limited or no prior exposure to methotrexate: the phase 3, randomised controlled FINCH 3 trial
por: Westhovens, René, et al.
Publicado: (2021)

Rituximab plus leflunomide in rheumatoid arthritis: a randomized, placebo-controlled, investigator-initiated clinical trial (AMARA study)
por: Behrens, Frank, et al.
Publicado: (2021)

A rheumatoid factor paradox: inhibition of rituximab effector function
por: Jones, Jonathan D, et al.
Publicado: (2013)

Evolution of radiographic joint damage in rituximab-treated versus TNF-treated rheumatoid arthritis cases with inadequate response to TNF antagonists
por: Finckh, Axel, et al.
Publicado: (2012)

Clinical, functional and radiographic consequences of achieving stable low disease activity and remission with adalimumab plus methotrexate or methotrexate alone in early rheumatoid arthritis: 26-week results from the randomised, controlled OPTIMA study
por: Kavanaugh, Arthur, et al.
Publicado: (2013)

Cost-effectiveness of infliximab versus conventional combination treatment in methotrexate-refractory early rheumatoid arthritis: 2-year results of the register-enriched randomised controlled SWEFOT trial
por: Eriksson, Jonas K, et al.
Publicado: (2015)

Long-term safety and efficacy of certolizumab pegol in combination with methotrexate in the treatment of rheumatoid arthritis: 5-year results from the RAPID 1 trial and open-label extension
por: Keystone, Edward, et al.
Publicado: (2014)

Sustained improvements in MRI outcomes with abatacept following the withdrawal of all treatments in patients with early, progressive rheumatoid arthritis
por: Peterfy, Charles, et al.
Publicado: (2016)

The Canadian Methotrexate and Etanercept Outcome Study: a randomised trial of discontinuing versus continuing methotrexate after 6 months of etanercept and methotrexate therapy in rheumatoid arthritis
por: Pope, Janet E, et al.
Publicado: (2014)

Long-term efficacy and safety of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis: findings from an open-label treatment extension
por: Ruperto, Nicolino, et al.
Publicado: (2009)

A systematic review and meta-analysis of rituximab combined with methotrexate versus methotrexate alone in the treatment of rheumatoid arthritis
por: Wang, Zhao, et al.
Publicado: (2020)

Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients
por: van Vollenhoven, Ronald F, et al.
Publicado: (2013)

Effectiveness and safety of the interleukin 6-receptor antagonist tocilizumab after 4 and 24 weeks in patients with active rheumatoid arthritis: the first phase IIIb real-life study (TAMARA)
por: Burmester, Gerd R, et al.
Publicado: (2010)

Safety and effectiveness of upadacitinib or adalimumab plus methotrexate in patients with rheumatoid arthritis over 48 weeks with switch to alternate therapy in patients with insufficient response
por: Fleischmann, Roy M, et al.
Publicado: (2019)

Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate
por: Keystone, Edward C, et al.
Publicado: (2015)

Belimumab and Rituximab in Systemic Lupus Erythematosus: A Tale of Two B Cell-Targeting Agents
por: Wise, Leanna M., et al.
Publicado: (2020)

Optimal dosage and route of administration of methotrexate in rheumatoid arthritis: a systematic review of the literature
por: Visser, K, et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_blo7vp05v0rd19solv9v7i6ggs